Overview
- 24 inspections across 23 sites are on record.
- 15 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2012-02-10.
At a glance
Inspections
24
Sites
23
Observations
15
Career since
Mar 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Shulin Wu MD | 10 Feb 2012 | ||
| Shiyao Wu MD | 3 Feb 2012 | On file | |
| SPI PHARMA | 29 Sep 2009 | On file | |
| Boehringer Ingelheim Labso | 22 Sep 2009 | On file | |
| Polypeptide Laboratories France | 16 Sep 2009 |
Sites inspected
Shulin Wu MDGuangzhou, China1 insp.
Shiyao Wu MDShanghai, China1 insp.
SPI PHARMASeptemes Les Vallons, France1 insp.
Boehringer Ingelheim LabsoBlanquefort Cedex, France1 insp.
Polypeptide Laboratories FranceStrasbourg, France1 insp.
Co-investigators
Investigators who share inspections with this person.
Thomas W Nojek4 shared
Anissa M Vargas3 shared
David P Moorhead2 shared
Byungja E Marciante1 shared
Maribeth G Grattan1 shared
Nadeem I Chaudhry1 shared
Christopher T Middendorf1 shared
Michael E Campbell1 shared
Nicholas L Paulin1 shared
Full investigator report
Get the verbatim findings behind Donna F Campbell's 15 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site